Pharvaris will present six abstracts on bradykinin-mediated diseases at the AAAAI 2026 Annual Meeting in Philadelphia.
Quiver AI Summary
Pharvaris, a biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for treating bradykinin-mediated diseases, announced the acceptance of six abstracts for poster presentations at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting in Philadelphia. This marks the company's first opportunity to present positive data from their RAPIDe-3 study and final results from the Phase 2 study of deucrictibant for hereditary angioedema (HAE). Key presentations will include findings on the health-related quality of life improvements from the CHAPTER-1 trial and pharmacokinetic data from the deucrictibant extended-release tablet being studied in the pivotal Phase 3 CHAPTER-3 trial, with topline results expected later in 2026. The abstracts will also be accessible through The Journal of Allergy and Clinical Immunology. Pharvaris aims to redefine the standard of care in treating HAE with its innovative therapies.
Potential Positives
- Acceptance of six abstracts for poster presentation at the AAAAI Annual Meeting highlights Pharvaris' active engagement in the scientific community and acknowledgment of its research efforts.
- Presentation of positive study results, including final data from the Phase 2 CHAPTER-1 study, reinforces the company's commitment to advancing treatment options for hereditary angioedema (HAE).
- Upcoming topline data from the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks is anticipated, indicating potential for significant market impact and further validation of the treatment's efficacy.
Potential Negatives
- Dependency on upcoming clinical trial results (CHAPTER-3) for future market validation poses a risk; any negative outcomes could significantly impact investor confidence and company reputation.
- Absence of detailed data or results in the press release may raise concerns among stakeholders about the transparency and robustness of the presented findings.
- Potential for heightened scrutiny and pressure on results, given the company's claims of offering a new standard of care, which sets high expectations for clinical efficacy and safety data forthcoming from CHAPTER-3.
FAQ
What is Pharvaris presenting at the AAAAI 2026 Annual Meeting?
Pharvaris will present six abstracts, including results from the Phase 2 CHAPTER-1 study and Phase 3 RAPIDe-3 study.
When will the AAAAI 2026 Annual Meeting take place?
The AAAAI Annual Meeting will be held from February 27 to March 2, 2026, in Philadelphia, PA.
What disease does Pharvaris focus on in their research?
Pharvaris develops treatments for bradykinin-mediated diseases, particularly hereditary angioedema (HAE) and acquired angioedema (AAE-C1INH).
Where can I find the abstracts presented by Pharvaris?
The abstracts are available online in The Journal of Allergy and Clinical Immunology supplement at jacionline.org.
What is the anticipated timeline for deucrictibant data release?
Topline data from the Phase 3 study of deucrictibant is expected in the third quarter of 2026.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$PHVS Hedge Fund Activity
We have seen 68 institutional investors add shares of $PHVS stock to their portfolio, and 15 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- EQT FUND MANAGEMENT S.A R.L. added 3,424,609 shares (+inf%) to their portfolio in Q3 2025, for an estimated $85,443,994
- WELLINGTON MANAGEMENT GROUP LLP added 1,734,743 shares (+inf%) to their portfolio in Q3 2025, for an estimated $43,281,837
- VR ADVISER, LLC removed 1,373,021 shares (-67.1%) from their portfolio in Q3 2025, for an estimated $34,256,873
- FMR LLC added 976,765 shares (+18.0%) to their portfolio in Q3 2025, for an estimated $24,370,286
- SATURN V CAPITAL MANAGEMENT LP added 886,332 shares (+inf%) to their portfolio in Q3 2025, for an estimated $22,113,983
- PARADIGM BIOCAPITAL ADVISORS LP added 772,583 shares (+72.7%) to their portfolio in Q3 2025, for an estimated $19,275,945
- KYNAM CAPITAL MANAGEMENT, LP added 675,000 shares (+inf%) to their portfolio in Q3 2025, for an estimated $16,841,250
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$PHVS Analyst Ratings
Wall Street analysts have issued reports on $PHVS in the last several months. We have seen 4 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Morgan Stanley issued a "Overweight" rating on 12/04/2025
- Guggenheim issued a "Buy" rating on 12/04/2025
- HC Wainwright & Co. issued a "Buy" rating on 11/13/2025
- Wedbush issued a "Outperform" rating on 11/13/2025
To track analyst ratings and price targets for $PHVS, check out Quiver Quantitative's $PHVS forecast page.
$PHVS Price Targets
Multiple analysts have issued price targets for $PHVS recently. We have seen 6 analysts offer price targets for $PHVS in the last 6 months, with a median target of $40.0.
Here are some recent targets:
- Justin Kim from Oppenheimer set a target price of $50.0 on 12/04/2025
- Tazeen Ahmad from B of A Securities set a target price of $30.0 on 12/04/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $39.0 on 12/04/2025
- Matthew Harrison from Morgan Stanley set a target price of $41.0 on 12/04/2025
- Patrick R. Trucchio from HC Wainwright & Co. set a target price of $60.0 on 12/03/2025
- Laura Chico from Wedbush set a target price of $30.0 on 11/13/2025
Full Release
ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), announced the acceptance of six abstracts for poster presentation, three of which will be presented during the Featured Poster session, at the American Academy of Allergy, Asthma & Immunology (AAAAI) 2026 Annual Meeting , to be held from February 27-March 2, 2026, in Philadelphia, PA.
“Following the announcement of topline RAPIDe-3 data in December of last year, the AAAAI Annual Meeting provides Pharvaris with the first opportunity to share the positive study results with the broader medical community at a large scientific congress,” said Peng Lu, M.D., Ph.D., Chief Medical Officer of Pharvaris. “We will also be presenting final data from the open-label portion of CHAPTER-1, the Phase 2 study of deucrictibant for prophylaxis of HAE attacks, and pharmacokinetic data of deucrictibant extended-release tablet, which is being used in the pivotal Phase 3 study of deucrictibant for long-term prophylaxis of HAE attacks, CHAPTER-3. Final efficacy and safety results from approximately three years of deucrictibant treatment from CHAPTER-1 and the data providing further evidence of an optimized extended-release formulation provide strong foundations in advance of the results of CHAPTER-3, topline data from which is anticipated in the third quarter of this year. Additionally, we will be presenting on-demand endpoint validation findings, as well as results from our novel kinin biomarker assay.”
Details of the presentations are as follows:
-
Title:
A Novel Kinin Biomarker Assay for Characterization of Different Types of Bradykinin-Mediated Angioedema
Presenter: Evangelia Pardali, Ph.D.
Poster Number: 078
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST -
Title:
Content Validity of the Angioedema syMptom Rating scAle (AMRA) to Assess Symptoms of Hereditary Angioedema Attacks
Presenter: Teresa Caballero, M.D., Ph.D.
Poster Number: 154
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST -
Title:
Long-Term Prophylactic Treatment with Oral Deucrictibant Improved Health-Related Quality of Life in Participants with Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: Michael E. Manning, M.D.
Poster Number: 159
Date, time: Friday, February 27, 2026, 2:45-3:45 p.m. EST -
Title:
Oral Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: Results of the Phase 3 RAPIDe-3 Study
Presenter: Marc A. Riedl, M.D., M.S.
Featured Poster Number: 831
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST -
Title:
Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Final Results of the Phase 2 CHAPTER-1 Open-Label Extension Study
Presenter: John Anderson, M.D.
Featured Poster Number: 832
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST -
Title:
Sustained Therapeutic Exposure with Once-Daily Oral Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks
Presenter: Zhi-Yi Zhang, Ph.D.
Featured Poster Number: 834
Date, time: Sunday, March 1, 2026, 3:30-5:00 p.m. EST
The abstracts are available to view in an online supplement to The Journal of Allergy and Clinical Immunology (JACI) at jacionline.org .
The posters and presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentations at: ir.pharvaris.com/news-events/events-presentations .
About Pharvaris
Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs in bradykinin-mediated conditions, including all types of bradykinin-mediated angioedema. Pharvaris’ aspiration is to offer therapies with injectable-like efficacy™, a well-tolerated profile, and the convenience of oral administration to prevent and treat bradykinin-mediated angioedema attacks. By delivering on this aspiration, Pharvaris aims to provide a new standard of care in bradykinin-mediated angioedema. Pharvaris is preparing global marketing authorization applications for deucrictibant immediate-release capsule as an on-demand treatment of HAE attacks, and a global pivotal Phase 3 study of deucrictibant extended-release tablet for the prevention of HAE attacks (CHAPTER-3) is ongoing with topline data anticipated in the third quarter of 2026. In addition, CREAATE is an ongoing Phase 3 study of deucrictibant for the prophylactic and on-demand treatment of AAE-C1INH attacks. For more information, visit
https://pharvaris.com/
.
